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OBJECTIVES This study sought to investigate the influence of stent design on the long-term angiographic
outcome.
BACKGROUND The proportional relationship between vessel injury and late luminal loss in percutaneous
revascularization should be best appreciated in coronary stenting, where recoil and shrinkage
are theoretically minimal. It is unclear whether all stent designs can counterbalance this
reactive loss by achieving a large initial luminal gain (bigger is better).
METHODS In 523 lesions successfully stented, the long-term angiographic results of slotted-tube (n 5
331), coil (n 5 85), multicellular (n 5 70) and self-expandable mesh (n 5 37) stent designs
were compared using the angiographic gain-loss relationship (GLR).
RESULTS Restenosis rate was 10% for multicellular, 20% for slotted-tube, 46% for coil and 49% for
self-expandable designs (p 5 0.001). At a difference with other designs, no significant GLR
was found in coil stents, suggesting additional mechanisms of luminal loss (i.e., plaque
protrusion, stent compression) to neointimal proliferation. Significant differences in late loss
between stents were found within each quartile of luminal gain, suggesting a specific role of
design in luminal loss. Multivariate analysis identified use of coil and self-expandable stents,
vessel size, minimal luminal diameter preintervention, luminal gain and stent length as
variables with independent predictive value for several indices of angiographic long-term
outcome.
CONCLUSIONS The analysis of GLR: 1) demonstrates that stent design influences late luminal loss; 2)
challenges the applicability of the widely accepted “bigger is better” approach to all stent
designs; and 3) appears as a valuable tool in assessing long-term stent performance. (J Am
Coll Cardiol 1999;34:1490–7) © 1999 by the American College of Cardiology
Although the growth of stenting is in large part due to the
demonstration in major randomized studies of its superior
long-term results when compared with balloon angioplasty
(1–3), restenosis still occurs in approximately 20% of cases.
In comparison with balloon angioplasty, in which elastic
recoil and vessel remodelling have been proposed as impor-
tant contributors to the luminal loss in the long term,
restenosis after coronary stenting is thought to be due
mainly to neointimal proliferation (4,5). In this regard, the
extent of the intimal proliferative response has been consis-
tently shown in experimental (6) and angiographic (7)
studies to bear a proportional relationship with the degree of
damage inflicted to the vessel during its revascularization.
Whether stent design might have an influence on the degree
of injury and the process of vascular repair, or in facilitating
other causes of luminal loss than neointimal proliferation
(stent recoil, insufficient scaffolding), remains undeter-
mined.
Based on these premises, in the present work, we study
the influence that stent design may play in the long-term
angiographic results, as judged by the relationship between
the luminal gain obtained during the procedure and the
luminal loss observed at angiographic follow-up.
METHODS
Study population. We included in the study all patients
successfully treated at our hospital with four basic stent
designs, who completed routine, prospective angiographic
follow-up and full quantitative angiographic analysis (as part
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of a prospective, programmed angiographic follow-up of all
patients treated with coronary stents), with the following
exclusion criteria: 1) total coronary occlusions and lesions
concomitantly treated with debulking techniques (laser or
atherectomy) or other revascularization devices (radiofre-
quency or cutting-balloon angioplasty); and 2) segments
treated with more than one stent configuration. Angio-
graphic success was defined as postprocedural diameter
stenosis ,50%.
Coronary stenting. Coronary stenting was performed with
four different basic stent designs: 1) self-expandable mesh
(Wallstent; Schneider, Bu¨lach, Switzerland); 2) slotted tube
(Palmaz-Schatz 153 series; Johnson and Johnson, Warren,
New Jersey); 3) balloon-expandable coil (Gianturco-Roubin
I and Gianturco Roubin II; Cook Inc., Bloomington,
Indiana); and balloon expandable multicellular (MultiLink;
Advanced Cardiovascular Systems, Santa Clara, California;
and NIR; Medinol/Scimed, Tel Aviv, Israel). The classifi-
cation of stents in these four categories is justified on the
following grounds. 1) The largest amount of information
available on the long-term outcome of coronary stenting is
based on the use of the Palmaz-Schatz stent, which there-
fore merits an individual category as a reference when
assessing the anti-restenosis effect of new stent designs (as
recommended by the U.S. Food and Drug Administration
stent equivalence trials). This design includes a central
articulation that, as discussed later, may be detrimental in
the long term. 2) Both multicellular stents have continuous
stainless steel designs without articulation and similar scaf-
folding properties, hoopstrength and total metal area when
expanded. 3) Both coil designs present similar flexibility,
strut pattern and metal surface when fully expanded and
have larger spacing between struts and lower collapse
pressure than the slotted tube and multicellular configura-
tions described above. 4) Alternatively, the Wallstent is a
self-expanding mesh that exerts a persistent radial force.
Detailed description of these stents, with extensive technical
documentation supporting the above discussion, can be
found elsewhere (8,9).
The procedure was performed using the femoral or
brachial artery approach, using 8F or 9F guiding catheters.
Patients were anticoagulated with heparin (initial bolus of
100 IU/kg body weight with additional boluses as required
by activated clotting time or duration of the angioplasty).
On-line quantitative angiography and intravascular ultra-
sound were not routinely used to guide the procedure, and
the final result was left to the judgment of the operator. All
stents were implanted after predilation. Angiographic suc-
cess was defined as a ,50% residual diameter stenosis.
Postprocedural medication included a minimum of 12 h of
intravenous infusion of heparin. Until 1994, treatment
included oral anticoagulation with a warfarin derivative
(dosage adjusted to keep the international normalized ratio
in the range of 3.5 to 4.5) and a calcium antagonist. Since
then, oral anticoagulation was not routinely indicated, and
oral aspirin ($150 mg/day) and ticlopidine (500 mg/day
during 2 days, subsequently 250 mg/day) was given instead.
Quantitative angiography. Cineangiography frames cor-
responding to basal, initial stenting and long-term
follow-up results were digitized and analyzed using a com-
mercially available automated edge detection quantitative
angiography system (Artrek; Quinton Imaging, Ann Arbor,
MI). The filmed catheter tip was used as a calibration
device. Intracoronary administration of 200 mg of nitroglyc-
erin was performed to ensure control of vasomotor tone. In
follow-up angiograms, particular attention was paid to
perform measurements at the site in which the stent was
deployed, either using the radiopacity of the prosthesis
(when visible) or angiographic landmarks. From the refer-
ence and minimal luminal diameters (MLDs) at each stage
Abbreviations and Acronyms
MLD 5 minimal luminal diameter
PTCA 5 percutaneous transluminal coronary angioplasty
Table 1. Baseline Characteristics of the Study Population
All Stents PS Coil Multicell
Self-
expandable
Lesions (% of all) 523 (100) 331 (63) 85 (16) 70 (14) 37 (7)
Restenotic 116 (22) 86 (26) 17 (20) 7 (10) 6 (16)
Left anterior descending artery location 275 (53) 176 (53) 53 (62) 32 (46) 14 (38)
Saphenous graft 28 (5) 19 (6) 0 0 9 (24)
Eccentric 431 (82) 256 (77) 76 (89) 62 (89) 37 (100)
Side branch 68 (13) 47 (14) 15 (18) 6 (9) 0
Bend 79 (15) 46 (14) 21 (25) 6 (9) 6 (16)
Calcium 53 (10) 22 (7) 14 (16) 9 (13) 8 (22)
Maximal balloon pressure (Atm) 10.61 6 3.56 10.27 6 3.44 9.93 6 3.11 12.35 6 3.44 11.95 6 4.30
Maximal balloon diameter (mm) 3.40 6 0.50 3.48 6 0.55 3.19 6 0.47 3.41 6 0.43 3.58 6 0.58
Length of stented segment (mm) 17.58 6 6.14 15.24 6 2.98 17.94 6 5.79 21.88 6 5.87 27.94 6 10.77
Data are mean 6 standard deviation. Percentages are shown in brackets.
PS 5 Palmaz-Schatz.
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of the study, a number of angiographic parameters were
obtained, including acute luminal gain (defined as the
increase in luminal diameter documented during the proce-
dure), late luminal loss (or the decrease in absolute dimen-
sions at follow-up of the initially achieved lumen), net gain
(or the difference between acute gain and late loss) and loss
index (the ratio between luminal loss and gain). Restenosis
rate was also defined as a dichotomous variable ($50%
diameter stenosis at follow-up).
Statistical analysis. A lesion-based approach was followed
(10,11). Univariate analysis was performed using the Stu-
dent t test for comparison of mean values (with Bonferroni’s
correction when required), and the chi-square for compar-
ison of percentages (with Yates correction when required).
Linear regression analysis was also performed using a
least-square approach. On the grounds of the luminal gain
obtained, the 523 lesions were divided into four approxi-
mately equal-sized groups, or quartiles. Within each of
these quartiles, comparisons between stent designs were
performed using one-way analysis of variance, with con-
comitant Fisher PLSD and Scheffe´-F tests. Multiple linear
regression analysis was used for multivariate modelling and
statistical adjustment to differences in baseline characteris-
tics between stent designs. Dummy variables were generated
Figure 1. Baseline and postprocedural quantitative angiography
data in the four stent designs. *Differences between stent design
with a Fisher PSLD with p , 0.05. MLD 5 minimal luminal
diameter.
Figure 2. Changes in luminal dimensions induced by the four
stent designs, derived from data in Figure 1. *Differences between
stent designs with a Fisher PSLD with p , 0.05.
Figure 3. Percent diameter stenosis at follow-up for the four stent
designs studied, displayed as cumulative frequency distribution
curves.
Figure 4. Late luminal loss per quartile of initial luminal gain
observed in the four stent designs studied. The bars indicate 95%
confidence intervals.
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to input the influence of stent design into the model, using
the Palmaz-Schatz design as a reference. A p , 0.05 was
considered significant.
RESULTS
From March 1990 to January 1997, a total of 5,609 coronary
stenoses were treated at our institution in 3,508 patients.
Coronary stents were implanted in 1,200 lesions. Of this
population, 207 were total occlusions, 30 had concomitant
atherectomy, 8 had concomitant laser percutaneous trans-
luminal coronary angioplasty (PTCA) and 34 had concom-
itant radiofrequency or cutting-balloon PTCA. Of the 921
remaining lesions, 29 were excluded due to failed stenting
and 8 due to subacute stent thrombosis. Twenty-two lesions
could not be followed due to patient death. A total of 197
lesions receiving two different stent designs and/or stent
designs not contemplated in the study were also excluded.
Angiographic follow-up of 96 lesions was not performed
due to patient refusal or contraindication for recatheteriza-
tion. The angiographic follow-up rate in eligible lesions
was, therefore, 86% (569/665 lesions) and was completed by
July 1997. During subsequent QCA analysis, 46 lesions
were found not suitable for adequate QCA assessment in
either pre-, postprocedural or follow-up frames and were
excluded. The final 523 lesions, present in 483 patients,
fulfilled the inclusion criteria of the study. Demographic
characteristics are shown in Table 1. Male gender was
predominant (410, 85%). Age was 59.3 6 10.2 years. In 443
(92%), one coronary segment was stented, while two or
three segments were treated with stents in 34 (7%) and 4
(1%) patients, respectively. The design used was self-
expandable mesh in 37 (7%) segments, slotted tube in 331
(63%), coiled wire in 85 (16%) and multicellular in 70
(14%). The angiographic characteristics of the lesions
treated are shown in Table 1. Prospective angiographic
follow-up was performed at 169 6 5 days.
Figure 1 shows baseline and postprocedural quantitative
angiographic data. Several statistically significant differences
between stent configurations were noted in quantitative
angiography variables, including vessel size, and MLD pre-,
poststenting and at follow-up. Adjustment for these differ-
ences was performed later using multivariate modelling.
Figure 2 shows absolute changes in luminal dimensions
induced by the four different stent designs. Multicellular
and self-expanding mesh designs were associated with the
largest acute luminal gain, followed by the slotted-tube and
coil designs. In spite of similar initial results, large differ-
ences in luminal loss, net gain and loss index between the
multicellular and self-expanding configurations were noted
in the long term, which favored the performance of the
multicellular design. On the contrary, the coil configuration
yielded significantly less acute luminal gain and presented
larger luminal loss in the long term. The net gain was thus
not different from that observed in the self-expanding
design.
Figure 3 shows the observed percent stenosis data at
follow-up for the four stent designs included in the study,
displayed as cumulative frequency distribution curves. The
disparate curves reflect significant variations in the resten-
osis rate observed with each device. Any definition of
percent diameter stenosis can be used to compare the
performance of the four stent designs. When defined as a
Table 2. Results of Univariate Linear Regression Analysis of Luminal Gain and Loss in the
Four Stent Designs Studied
Design Regression equation R Coefficient p
Multicellular Loss 5 0.44Gain 20.36 0.36 0.001
Self-expandable Loss 5 0.73Gain 20.31 0.42 0.008
Coil Loss 5 20.00Gain 11.02 0.00 NS
Tubular slotted Loss 5 0.24Gain 10.20 0.18 0.008
Table 3. Comparison of Luminal Loss in Each of the Stents Designs Used Within Each
Quartile of Luminal Gain
Design
Luminal Loss
Quartile 1
(0.34–1.77 mm)
(n 5 130)
Quartile 2
(1.78–2.12 mm)
(n 5 130)
Quartile 3
(2.13–2.50 mm)
(n 5 132)
Quartile 4
(2.51–3.89 mm)
(n 5 131)
Slotted tube 0.46 6 0.72 0.78 6 0.71 0.92 6 0.84 0.72 6 0.76
Coil 0.89 6 0.77 1.17 6 0.90 1.23 6 0.70 0.55 6 0.87
Self-expandable 0.84 6 1.10 1.18 6 1.16 1.48 6 0.70 1.67 6 1.00
Multicellular 0.35 6 0.71 0.42 6 0.41 0.64 6 0.58 0.93 6 0.59
p 5 0.03 p 5 0.008 p 5 0.01 p 5 0.0001
Mean 6 standard deviation
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$50% diameter stenosis at follow-up, restenosis rate was
10%, 20%, 46% and 49% for the multicellular, slotted tube,
coil and self-expandable mesh configurations, respectively
(p 5 0.001). Total occlusion at follow-up occurred in 16
(3%) cases: 9 (3%) in the Palmaz-Schatz, 4 (5%) in the coil,
3 (8%) in the self-expandable and none in the multicellular
designs (p 5 NS). Exclusion of these 16 cases did not
influence the conclusions outlined in the previous para-
graphs.
The results of the univariate linear regression analysis of
the gain-loss relationship are shown in Table 2. A propor-
tional, statistically significant relationship between gain and
loss was demonstrated in all but one stent type, the coil
design, in which no statistically significant relation between
both parameters was found. This difference could not be
ascribed to differences in population size between groups.
Within each quartile of luminal gain, significant differences
in luminal loss between the four stent designs were found
(Table 3 and Fig. 4). No significant differences in vessel size
in the four designs within each quartile were noted.
Table 4 shows the result of multivariate analysis used as a
technique of adjustment for baseline differences between
groups and modelling. In accordance with most ongoing
equivalence trials on coronary stenting, the Palmaz-Schatz
design was used as a reference by not being entered in the
model as a dummy variable. The variables MLD, postin-
tervention and percent diameter stenosis were not entered in
the model, because the presence of the variables MLD
before luminal gain and vessel diameter would make the
model colinear (the only exception being loss index, in
which luminal gain had no independent predictive value).
Their influence in the model is, however, maintained by the
Table 4. Results of Multiple Regression Analysis for Minimal Luminal Diameter, Luminal Loss
and Net Luminal Gain at Follow-up
Beta Coefficient
(95% CI)
p
Value
MLD at follow-up
Intercept 20.20
Gain 0.47 (0.28, 0.66) ,0.0001
Vessel size 0.37 (0.16, 0.57) 0.0005
Total stent length 20.01 (20.02, 0.00) 0.03
MLD pre 0.50 (0.23, 0.78) 0.0003
Coil design 20.35 (20.55, 20.14) 0.0007
Self-expandable design 20.55 (20.85, 20.24) 0.001
Model R 5 0.54 R2 5 0.29 p , 0.0001
Luminal loss
Intercept 0.20
Gain 0.52 (0.34, 0.71) ,0.0001
Vessel size 20.37 (20.57, 20.16) 0.0005
Total stent length 0.01 (0.00, 0.02) 0.03
Coil design 0.35 (0.14, 0.55) 0.0007
Self-expandable design 0.55 (0.24, 0.85) 0.0004
Model R 5 0.35 R2 5 0.13 p , 0.0001
Net luminal gain
Intercept 20.20
Gain 0.47 (0.28, 0.66) ,0.0001
Vessel size 0.37 (0.16, 0.57) 0.0005
Total stent length 20.01 (20.02, 0.00) 0.03
MLD preprocedure 20.49 (20.76, 20.21) 0.0005
Coil design 20.35 (20.55, 20.14) 0.0007
Self-expandable design 20.55 (20.85, 20.24) 0.0004
Model R 5 0.55 R2 5 0.31 p , 0.0001
Loss index
Intercept 0.54
MLD postprocedure 0.15 (0.32, 0.77) ,0.004
Vessel size 20.27 (20.32, 20.08) 0.0006
Coil design 0.24 (0.14, 0.34) ,0.0001
Self-expandable design 0.30 (0.16, 0.43) ,0.0001
Model R 5 0.52 R2 5 0.08 p , 0.0001
CI 5 confidence interval; MLD 5 minimal luminal diameter.
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remaining variables. The variables that retained statistically
significant predictive value after a discriminant approach
were vessel size, MLD preintervention, luminal gain, length
of the stented segment and use of coil or self-expanding
mesh designs. When loss index was taken as the dependent
variable, luminal gain had no independent predictive value.
The variable MLD post had an independent predictor value
and was entered in the model instead. Other variables such
as restenotic lesion, left anterior descending location, saphe-
nous graft, eccentricity, presence of side branch, bend or
calcium did not influence the statistical strength of the
model or have independent predictive value on the above-
mentioned variables and were therefore excluded.
DISCUSSION
The more you gain, the more you lose. Vascular damage
caused during lesion revascularization is accepted as the
initiating phenomenon of a variety of pathophysiological
mechanisms that eventually lead to restenosis (4,5). As a
corollary to this response-to-injury phenomenon, experi-
mental and angiographic research first demonstrated the
existence in humans and some animal models of a propor-
tional relationship between the degree of vessel wall damage
and the subsequent degree of neointimal proliferation and
luminal loss (6,12). Subsequently, differences in restenosis
propensity between percutaneous revascularization devices
were reported, paralleling the gain-loss relationship and
suggesting that, in addition to the absolute luminal gain,
device-specific effects of wall injury resulted in variable
neointimal proliferative responses, which were considered
the main substrate of restenosis (7). It is now accepted that
the angiographically determined luminal loss might result
not only from neointimal proliferation but also from: 1) the
phenomenon of vessel remodelling or shrinkage (13); and 2)
differences in the luminal shape resulting from each device
(which, as demonstrated with intracoronary imaging tech-
niques, may cause major inaccuracies during the angio-
graphic assessment of the acute result of the interven-
tion)(14).
Bigger is better. Alternatively, it has been suggested that
the ability of a revascularization device to reduce restenosis
is more related to its ability to provide the greatest acute
luminal gain than its ability to reduce subsequent intimal
hyperplasia (15). This would be the case of devices that
generate a large luminal gain and concomitantly present a
favorable slope of the gain-loss relationship, leading to a
favorable net luminal gain. The concept has gained wide
acceptance after major trials comparing PTCA and stenting
demonstrated that the superiority of the latter in reducing
restenosis relies on achievement of a large initial luminal
gain and not on absolute reduction of luminal loss (1–3).
Bigger is not always better. In this work, we focused our
attention on the potential use of the gain-loss relationship in
comparing different coronary stent designs. Theoretically,
restenosis after stenting should be a direct result of neoin-
timal proliferation (elastic recoil and vessel shrinkage should
be minimal), and the reliability of the angiographic luminal
gain and loss should be maximal due to the round luminal
morphology achieved by stenting. Lesions concomitantly
treated with other revascularization techniques (which
might modify the propensity to restenosis) and total coro-
nary occlusions, in which an increased restenosis rate after
stenting has been reported (16), were excluded. The results
obtained provide new insights on the apparent conflict
between the two bodies of knowledge outlined above by
demonstrating that, with independence of the luminal gain
achieved, stent design may significantly influence long-term
outcome. In this regard, the analysis of the gain-loss
relationship constitutes a valuable tool in comparing the
performance of several stent configurations. Taking the
performance of self-expanding mesh and multicellular stents
in our study, significant differences in luminal loss between
both designs were documented within each quartile of
luminal gain. The continuous and proportional relationship
between luminal gain and loss through all the quartiles of
luminal gain for both designs suggests that the leading
mechanism contributing to luminal loss in these two stent
configurations is the generation of neointimal hyperplasia.
Although both stent designs rendered excellent and similar
initial angiographic results, the disparate differences in
neointimal proliferation clearly affected the long-term out-
come of the self-expanding design. The approach of obtain-
ing a large luminal gain with the sole aim to reduce
restenosis is thus challenged.
Conversely, the implantation of coil stents was associated
with less initial gain and significantly large luminal losses
during follow-up. An intriguing observation is that, in this
design, the relationship between luminal gain and loss was
statistically nonexistent. Following the rationale outlined in
the previous paragraph, a plausible explanation is that
luminal loss in this design derives not only from neointimal
proliferation but also from factors not proportionally related
to the degree of vessel damage, such as the following: 1)
plaque prolapse through the free space between stent struts
(this design presents the largest gaps) (17); 2) more stent
recoil than in other designs (as demonstrated with intravas-
cular ultrasound imaging) (18); and 3) a higher propensity
of the coil design to restenose in the lower than in the upper
quartiles of luminal gain, in agreement with the results of
the GR II Stent Trial (19). In this regard, the long-term
performance of the coil stent in the upper quartile of luminal
gain was similar to that of the multicellular and Palmaz-
Schatz designs.
The Palmaz-Schatz 153 stent demonstrated a statistically
significant proportional relationship between gain and loss.
Per-quartile analysis suggests that the performance of this
stent also improves in the upper quartile of luminal gain. In
support of these findings, intracoronary ultrasound in
Palmaz-Schatz stents has demonstrated a clear relationship
between incomplete expansion and the volume of neointi-
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mal hyperplasia (20). Because cross-sectional metal coverage
of a stent is influenced by the degree of stent expansion, it
remains plausible that these designs facilitate the develop-
ment of restenosis in the lower quartiles of luminal gain.
Plaque prolapse between between the two stent subunits
(21) may also be more relevant under those circumstances.
Keeping in mind the limitations inherent in animal
models of vascular disease, there is experimental evidence
supporting the concept that stent design influences resten-
osis (22–25). Wall injury is mainly dictated by stent con-
figuration and not by wall stretching (22,23). Multicellular
designs generate 38% less neointimal hyperplasia than
slotted-tube stents (22). The delivery of pressure by each
individual strut on the vessel wall may substantially vary
between different designs, particularly if, like in the self-
expandable stent, there is strut overlap and chronic outward
expansion of the stent (26). Some strut patterns may be less
favorable than others in facilitating endothelial cell conflu-
ence and reendothelialization. Finally, plaque prolapse or
insufficient stent expansion may also lead to suboptimal
hemorrheology.
In agreement with previous works, we also found that
vessel size influences the long-term result of stenting,
favoring larger vessels (1,3,27). A small MLD preinterven-
tion was associated with increased luminal loss, as recently
reported after stenting (27) and previously after PTCA (10).
The length of the stented segment is also a well-known
predictor of restenosis (27). Balloon pressure did not sig-
nificantly influence long-term angiographic outcome (27).
Unlike with other studies (3,28), LAD location was not
identified as an independent predictor of long-term result.
Study limitations. The present work is representative of
the practice in a large hospital with wide experience in
coronary stenting, but, being nonrandomized, it may not be
free from inadvertent selection bias (i.e., selection according
to specific anatomic characteristics by the operator). Al-
though there were baseline differences between groups,
multivariate analysis was performed as a technique of
statistical adjustment, allowing their comparison. The anti-
thrombotic drug regimen used in the study was not con-
stant, following the changes in worldwide stent practice
during the last five years. Finally, intravascular ultrasound
was not routinely used to guide stent deployment.
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